<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943303</url>
  </required_header>
  <id_info>
    <org_study_id>T015-M02-2019AF002</org_study_id>
    <secondary_id>TO#617/2018</secondary_id>
    <nct_id>NCT03943303</nct_id>
  </id_info>
  <brief_title>Effects of Sand Treatment on Osteoarthritis</brief_title>
  <official_title>Effect of Monazite Sands in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Vila Velha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Vila Velha</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      2528/5000 Historically the city of Guarapari / ES is known as the city health by the popular
      therapeutic effect of its sands in diverse diseases. The articular diseases are among the
      list of the aggravations that popularly the monazitic sands exert some therapeutic effect,
      emphasizing. Rheumatic diseases include osteoarthritis of the knee. It is a disease with a
      high prevalence and in recent years have presented an increase in the incidence supposedly
      caused by the aging population and due to the epidemic of obesity. Osteoarthrosis is proven
      to be a disease that leads to the incapacity and restriction of the individual's ability to
      come and go with high monetary costs for the patient and the government. In view of these
      facts presented, the objective is to investigate the therapeutic potential of monazite sands
      in elderly patients submitted to serial, controlled and standardized exposure, compared to
      patients exposed to beach sand without radiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A sample of 150 patients with primary knee osteoarthrosis will be selected for the study,
      divided into two random groups that will be exposed to sand (one monazite sand group and
      another beach sand group without radiation) for 12 months. The groups will be evaluated at
      time 0 (at the patient's arrival in the group) and at 1, 2, 3, 6, 9 and 12 months of exposure
      following the literature criteria for evaluation of knee osteoarthrosis (Visual Analogue
      Scale (EVA) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)) and
      non-specific and specific biomarkers (C-reactive protein, erythrocyte sedimentation rate,
      IL-1β, IL-6, IL-8, TGF-β, and TNF-α). In addition, the groups will undergo an initial
      interview and monitoring of the pharmacological therapies used prior to the study and during
      the months of follow-up using the Dáder methodology of pharmaceutical care adapted to the
      study. As a result, the scientific evidence of the efficacy of monazitic sands in knee
      osteoarthrosis is expected not only by clinical criteria but also by laboratory evidence on
      the markers of the inflammatory and degenerative process that allow us to document the real
      value of the monazitic sands for health of the population, to establish a great line of
      research for the state of Espírito Santo and to value the State of Espírito Santo and the
      municipality of Guarapari as potential itineraries for SPA tourism (aiming to improve
      health).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">August 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will be carried out on the beaches of Areia Preta de Guarapari (source of monazitic sands) and on the beach of Itapoã in Vila Velha (sand without radiation). Selected patients will have their knees fully covered with beach sand, properly analyzed for radioactivity and temperature, for 30 minutes on 2 mornings a week for a period of 1 (one) year.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The outcomes assessor is unaware of the treatment that the patients received.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Visual analgesic scale (0-10)</measure>
    <time_frame>1, 3, 6, 8 and 12 months</time_frame>
    <description>Change pain perception through the visual analgesic scale of the volunteers. It consists of a graduated scale of 0 to 10 with regular intervals where zero means absence of pain and 10 is the maximum pain already experienced by the patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change total score (0 - 96) the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)- (lower scores indicate lower levels of symptoms or physical disability)</measure>
    <time_frame>1, 3, 6, 8 and 12 months</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire comprises three subscale. The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change the number of patient with higher concentration of Nonspecific inflammatory markers</measure>
    <time_frame>1, 3, 6, 8 and 12 months</time_frame>
    <description>Quantification of nonspecific inflammatory markers (HSV and CRP) and specific (IL-1β, IL-6, IL-8, IL-17, TNF-α and TGF-β) per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change the frequency of Self-medicatition to treat pain</measure>
    <time_frame>1, 3, 6, 8 and 12 months</time_frame>
    <description>Evaluation of the frequency of self-medication before and during the intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Osteo Arthritis Knee</condition>
  <arm_group>
    <arm_group_label>Natural gamma radiation from the monazite sands</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day. The natural gamma radiation doses of the monazite sands will be monitored, the radiation measurements gamma will be associated with the atmospheric and climatic measurements of each group. It is understood here as atmospheric measurements, level of solar radiation, spectrum of sunlight at the time of exposure, humidity, wind speed, ultraviolet radiation level, amount of ions present in the air and measurements of the magnetic field in the place.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal sands exposure patients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day. To ensure the absence of radiation, mesuaraments of possible radiation will be monitored.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Natural gamma radiation from the monazite sands</intervention_name>
    <description>Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.</description>
    <arm_group_label>Natural gamma radiation from the monazite sands</arm_group_label>
    <other_name>Natural beach black sands</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Normal sands exposure patients</intervention_name>
    <description>Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.</description>
    <arm_group_label>Normal sands exposure patients</arm_group_label>
    <other_name>No-monazite sands</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Joint pain related to daily activities;

          -  No morning joint stiffness greater than 30 minutes;

          -  Age between 30 and 95 years.

        Exclusion Criteria:

          -  History of previous knee surgery.

          -  History of fracture in the knee region.

          -  History of any secondary OA associated with any cystic arthropathy.

          -  Any treatment for the knee with methotrexate.

          -  History of hemorrhagic disorders.

          -  History of any infiltration of the knee during the previous 6 months (eg
             corticosteroids and hyaluronic acid).

          -  Morbid obesity.

          -  History of severe psychiatric disorders.

          -  History of skin cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DENISE C Endringer, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UVila Velha</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DENISE C ENDRINGER, Dr</last_name>
    <phone>+552732412146</phone>
    <email>denise.endringer@uvv.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcio Fronza, Dr</last_name>
    <phone>+552732412187</phone>
    <email>marcio.fronza@uvv.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Denise Coutinho Endringer</name>
      <address>
        <city>Vila Velha</city>
        <state>ES</state>
        <zip>29103790</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DENISE C ENDRINGER, Dr</last_name>
      <phone>+552734212146</phone>
      <email>denise.endringer@uvv.br</email>
    </contact>
    <contact_backup>
      <last_name>Marcio Fronza</last_name>
      <phone>+552732412187</phone>
      <email>marcio.fronza@uvv.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.theglobalhealthnetwork.org</url>
    <description>The Global Health Network template.</description>
  </link>
  <results_reference>
    <citation>Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med. 1969 Oct;62(10):989-93. Review.</citation>
    <PMID>4899510</PMID>
  </results_reference>
  <results_reference>
    <citation>Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988 Dec;15(12):1833-40.</citation>
    <PMID>3068365</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Vila Velha</investigator_affiliation>
    <investigator_full_name>Denise Coutinho Endringer</investigator_full_name>
    <investigator_title>Director of Research and graduate program</investigator_title>
  </responsible_party>
  <keyword>monazitc sands</keyword>
  <keyword>radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form: Protocol and statistical analysis</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03943303/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form: Inform consent</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03943303/Prot_ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Pharmaceutical care</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03943303/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Screening_log</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03943303/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Enrolment _log</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03943303/Prot_004.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Withdrawal_log</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03943303/Prot_005.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Telephone_Contact_Log</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03943303/Prot_006.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Meeting_minutes_template</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03943303/Prot_007.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

